Jul 14, 2016
Myasthenia gravis is a disorder characterized by proximal weakness, ptosis, and antibody formation against proteins at the neuromuscular junction. Most commonly, the protein targeted by antibodies is the nicotinic acetylcholine receptor. However, research in the last 2 decades has identified a number of other antibody targets, which we have reviewed here in this BrainWaves brief. BrainWaves podcasts and online content are intended for medical education only and should not be used to guide medical decision making in routine clinical practice. Any cases discussed in this episode are fictional and do not contain any patient health identifying information. The content in this episode was vetted and approved by Grant T. Liu. REFERENCES 1. Gilhus NE and Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. The Lancet Neurology. 2015;14:1023-36. 2. Hurst RL and Gooch CL. Muscle-Specific Receptor Tyrosine Kinase (MuSK) Myasthenia Gravis. Current neurology and neuroscience reports. 2016;16:61. 3. Koneczny I, Cossins J and Vincent A. The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis. J Anat. 2014;224:29-35. 4. Dalmau J and Rosenfeld MR. Paraneoplastic syndromes of the CNS. The Lancet Neurology. 2008;7:327-40. 5. Evoli A and Lancaster E. Paraneoplastic disorders in thymoma patients. J Thorac Oncol. 2014;9:S143-7.